In addition, both MERTK and PROS1 were upregulated in osimertinib-resistant mtEGFR NSCLC cell line derivatives and in mtEGFR NSCLC xenograft tumors treated with osimertinib. Here, PROS1 is linked to non-small cell lung carcinoma.